Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun Sees New Prescriptions Drought Amid COVID-19

But Situation Improving And Ilumya Solid

Executive Summary

Sun Pharma says that the first quarter of financial 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.

You may also be interested in...



Sun Sees Urgency To Establish Low Dose Absorica In US

Sun’s key specialty asset Ilumya makes progress, albeit slowly, in the US, while the firm sees ‘short window’ to ensure that Absorica LD gains grip in that market ahead of impending arrival of generic.

Sun Upbeat On IL-23 Prospects In US, Ilumya Faring ‘Reasonably’

Sun expects interleukin-23-targeting drugs to stay a preferred treatment option for psoriasis in the US and saw some sales uptick for its Ilumya in that market in Q2, although it isn’t keen on an auto injector option. Management was also upbeat on prospects in China and Japan.

Sun’s Ilumya Set For Phase III In Psoriatic Arthritis After ‘Promising’ Results

Sun releases what it says are promising interim data from a Phase II study on Ilumya, its flagship first novel biologic, in the additional indication of psoriatic arthritis, where the antibody met the primary endpoint in its first trial in this setting.

Topics

Related Companies

UsernamePublicRestriction

Register

MT142350

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel